Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/BOR.0000000000000308 http://scihub22266oqcxt.onion/10.1097/BOR.0000000000000308 C4965280!4965280!27270345     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Rheumatol 2016 ; 28 (5): 453-9 Nephropedia Template TP {{tp|p=27270345|t=2016. Cutaneous Lupus Erythematosus: Updates on Pathogenesis and Associations with Systemic Lupus |pdf=|usr=}}{{27270345}} gab.com Text Cutaneous Lupus Erythematosus: Updates on Pathogenesis and Associations with Systemic Lupus JO: Curr Opin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=27270345 #FOAvip Purpose of Review: Cutaneous lupus erythematosus (CLE) is a common manifestation among systemic lupus patients. There are no FDA approved therapies for CLE, and these lesions are frequently disfiguring and refractory to treatment. This will review will cover the recent inroads made into understanding the mechanisms behind CLE lesions and discuss promising therapeutic developments. Recent Findings: The definition of cutaneous lupus is being refined to facilitate diagnostic and research protocols. Research into the pathogenesis of CLE is accelerating, and discoveries are now identifying genetic and epigenetic changes which may predispose to particular disease manifestations. Further, unique features of disease subtypes are being defined. Murine work supports a connection between cutaneous inflammation and systemic lupus disease activity. Importantly, human trials of type I interferon blockade hold promise for improving our treatment armamentarium for refractory CLE lesions. Summary: Continued research to understand the mechanisms driving CLE will provide new methods for prevention and treatment of cutaneous lesions. These improvements may also have important effects on systemic disease activity, and thus, efforts to understand this link should be supported. Twit Text FOAVip Cutaneous Lupus Erythematosus: Updates on Pathogenesis and Associations with Systemic Lupus ????Curr Opin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=27270345 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27270345 #FOAvip English Wikipedia <ref>{{Cite pmid|27270345}}</ref> Cutaneous Lupus Erythematosus: Updates on Pathogenesis and Associations with Systemic Lupus #MMPMID27270345 Stannard JN; Kahlenberg JM Curr Opin Rheumatol 2016[Sep]; 28 (5): 453-9 PMID27270345show ga Purpose of Review: Cutaneous lupus erythematosus (CLE) is a common manifestation among systemic lupus patients. There are no FDA approved therapies for CLE, and these lesions are frequently disfiguring and refractory to treatment. This will review will cover the recent inroads made into understanding the mechanisms behind CLE lesions and discuss promising therapeutic developments. Recent Findings: The definition of cutaneous lupus is being refined to facilitate diagnostic and research protocols. Research into the pathogenesis of CLE is accelerating, and discoveries are now identifying genetic and epigenetic changes which may predispose to particular disease manifestations. Further, unique features of disease subtypes are being defined. Murine work supports a connection between cutaneous inflammation and systemic lupus disease activity. Importantly, human trials of type I interferon blockade hold promise for improving our treatment armamentarium for refractory CLE lesions. Summary: Continued research to understand the mechanisms driving CLE will provide new methods for prevention and treatment of cutaneous lesions. These improvements may also have important effects on systemic disease activity, and thus, efforts to understand this link should be supported. äCutaneous Lupus Erythematosus: Updates on Pathogenesis and Association(epmc).pdf DeepDyve Pubget Overpricing